Tag - TPST

Executive Moves

Tempest appoints Drake Richey and Dr. John Yee to BoD

Tempest Therapeutics (NASDAQ: TPST) has appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its board of directors (BoD), effective June 4, 2026. Mr. Richey and Dr. Yee collectively bring decades...

June 5, 2026

Markets

WB starts Tempest Therapeutics at OP

William Blair initiated coverage of Tempest Therapeutics (NASDAQ:TPST) with an “outperform” rating based on the potential of the company’s three first-in-class programs, including the dual EP2/EP4 antagonist, TPST-1495...

October 21, 2021

Tag - TPST

Tempest appoints Drake Richey and Dr. John Yee to BoD

WB starts Tempest Therapeutics at OP

Subscribe